Skip to main content
. 2023 Oct 26;11:57. doi: 10.1038/s41413-023-00295-4

Fig. 5.

Fig. 5

Effects of MS2 on bone formation in wild-type and compound Pkd1/Wwtr1Oc-cKO null mice. a Bone mineral density by DEXA scan. b Bone structure by micro-CT 3D images analysis. c Periosteal mineral apposition rate (MAR) by Calcein double labeling. d Osteoclast activities by TRAP immunostaining after MS2 (50 mg·kg−1) treatment for 4 weeks compared to vehicle control. Data are mean ± S.D. from 6 tibias of wild-type control and compound Pkd1/Wwtr1Oc-cKO null mice. *P < 0.05, **P < 0.01, ***P < 0.001 compared with wild-type control mice. P values were determined by 1-way ANOVA with Tukey’s multiple-comparisons test